TherapeuticsMD Inc (NASDAQ:TXMD) Insider John C.K. Iv Milligan Purchases 15,000 Shares of Stock

TherapeuticsMD Inc (NASDAQ:TXMD) insider John C.K. Iv Milligan bought 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average price of $3.16 per share, for a total transaction of $47,400.00. Following the acquisition, the insider now directly owns 1,472,419 shares of the company’s stock, valued at approximately $4,652,844.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of TherapeuticsMD stock traded up $0.22 on Thursday, hitting $2.95. The stock had a trading volume of 2,059,582 shares, compared to its average volume of 3,804,475. TherapeuticsMD Inc has a twelve month low of $1.82 and a twelve month high of $6.94. The company has a 50 day moving average price of $2.45. The company has a current ratio of 3.39, a quick ratio of 3.28 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $641.65 million, a PE ratio of -5.00 and a beta of 1.90.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Tuesday, August 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01). TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 163.84%. The firm had revenue of $6.08 million during the quarter, compared to analyst estimates of $5.12 million. During the same period in the previous year, the company posted ($0.15) EPS. TherapeuticsMD’s revenue for the quarter was up 60.0% compared to the same quarter last year. On average, equities research analysts expect that TherapeuticsMD Inc will post -0.73 EPS for the current year.



A number of equities analysts have weighed in on TXMD shares. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of TherapeuticsMD in a research report on Wednesday, August 7th. ValuEngine raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. lowered their price target on TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, June 11th. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. Finally, Jefferies Financial Group lowered their price target on TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating on the stock in a research report on Monday, July 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $9.28.

Several institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in shares of TherapeuticsMD by 3.0% in the first quarter. JPMorgan Chase & Co. now owns 20,435,672 shares of the company’s stock valued at $99,521,000 after purchasing an additional 601,899 shares during the last quarter. FMR LLC grew its position in shares of TherapeuticsMD by 0.5% in the first quarter. FMR LLC now owns 18,178,211 shares of the company’s stock valued at $88,527,000 after purchasing an additional 89,870 shares during the last quarter. BlackRock Inc. grew its position in shares of TherapeuticsMD by 3.7% in the second quarter. BlackRock Inc. now owns 15,991,138 shares of the company’s stock valued at $41,577,000 after purchasing an additional 576,601 shares during the last quarter. Vanguard Group Inc. grew its position in shares of TherapeuticsMD by 5.7% in the second quarter. Vanguard Group Inc. now owns 14,562,689 shares of the company’s stock valued at $37,862,000 after purchasing an additional 788,467 shares during the last quarter. Finally, Frontier Capital Management Co. LLC grew its position in shares of TherapeuticsMD by 291.5% in the first quarter. Frontier Capital Management Co. LLC now owns 5,857,096 shares of the company’s stock valued at $28,524,000 after purchasing an additional 4,360,963 shares during the last quarter. 80.81% of the stock is currently owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Read More: Bar Chart

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.